Pharmamarketeer

US FDA approves Lilly’s Cyramza to treat patients with hepatocellular carcinoma

Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with

Medhc-fases-banner
Advertentie(s)